JP2002508766A - 心不全の治療方法 - Google Patents

心不全の治療方法

Info

Publication number
JP2002508766A
JP2002508766A JP50505699A JP50505699A JP2002508766A JP 2002508766 A JP2002508766 A JP 2002508766A JP 50505699 A JP50505699 A JP 50505699A JP 50505699 A JP50505699 A JP 50505699A JP 2002508766 A JP2002508766 A JP 2002508766A
Authority
JP
Japan
Prior art keywords
dose
inotropic
positive
heart failure
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50505699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508766A5 (cg-RX-API-DMAC7.html
Inventor
アール. ブリストー、マイケル
Original Assignee
ユニバーシティ テクノロジー コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ テクノロジー コーポレイション filed Critical ユニバーシティ テクノロジー コーポレイション
Publication of JP2002508766A publication Critical patent/JP2002508766A/ja
Publication of JP2002508766A5 publication Critical patent/JP2002508766A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50505699A 1997-06-25 1998-06-24 心不全の治療方法 Pending JP2002508766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5067497P 1997-06-25 1997-06-25
US60/050,674 1997-06-25
PCT/US1998/013442 WO1998058638A1 (en) 1997-06-25 1998-06-24 Method of treating heart failure

Publications (2)

Publication Number Publication Date
JP2002508766A true JP2002508766A (ja) 2002-03-19
JP2002508766A5 JP2002508766A5 (cg-RX-API-DMAC7.html) 2005-12-08

Family

ID=21966696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50505699A Pending JP2002508766A (ja) 1997-06-25 1998-06-24 心不全の治療方法

Country Status (6)

Country Link
US (1) US5998458A (cg-RX-API-DMAC7.html)
EP (1) EP1017376A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002508766A (cg-RX-API-DMAC7.html)
AU (1) AU731656B2 (cg-RX-API-DMAC7.html)
CA (1) CA2295094A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998058638A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503356A (ja) * 2017-01-03 2020-01-30 カルディオキシル ファーマシューティカルズ,インク. ニトロキシル供与性化合物の投与方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
US7020521B1 (en) 2002-11-08 2006-03-28 Pacesetter, Inc. Methods and apparatus for detecting and/or monitoring heart failure
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼiv阻害剤の使用
US20060018970A1 (en) * 2003-12-12 2006-01-26 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
CN104644627A (zh) 2004-09-14 2015-05-27 科罗拉多大学董事会 基于基因靶向使用布新洛尔的治疗方法
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
WO2007014029A2 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
EP4146215A4 (en) * 2020-05-04 2024-05-01 Imbria Pharmaceuticals, Inc. DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354851B (cg-RX-API-DMAC7.html) * 1970-02-18 1973-03-26 Haessle Ab
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503356A (ja) * 2017-01-03 2020-01-30 カルディオキシル ファーマシューティカルズ,インク. ニトロキシル供与性化合物の投与方法

Also Published As

Publication number Publication date
WO1998058638A1 (en) 1998-12-30
CA2295094A1 (en) 1998-12-30
EP1017376A4 (en) 2002-10-25
EP1017376A1 (en) 2000-07-12
US5998458A (en) 1999-12-07
AU731656B2 (en) 2001-04-05
AU8174098A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
US5998458A (en) Method of treating heart failure
US7829596B2 (en) Methods of treatment
Zimmerman et al. Vasopressors and inotropes
JP2022020624A (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのnep阻害剤
Schmitt et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40‐5967 in patients with hypertension
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
Ventetuolo et al. WHO Group 1 pulmonary arterial hypertension: current and investigative therapies
US8778897B2 (en) Method of treatment using α-1-adrenergic agonist compounds
JP2018516267A (ja) 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
TW201302203A (zh) A2b腺苷受體拮抗劑於在心肌梗塞後之病患內治療心衰竭及心律不整上之用途
JP2014505106A (ja) 肺高血圧症を処置するための方法
Strain et al. Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure
Oyama et al. Dose-dependent effects of esmolol-epinephrine combination therapy in myocardial ischemia and reperfusion injury
WO2015069839A1 (en) Combination therapy for treating pulmonary hypertension
WO2007140181A2 (en) Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
Goldenberg et al. New inotropic drugs for heart failure
Wu et al. Iloprost and exercise haemodynamics in heart failure with preserved ejection fraction—the ILO‐HOPE randomised controlled trial
Malinowski et al. Next-generation small molecule therapies for heart failure: 2015 and beyond
Watson et al. Beta2-adrenergic activation via administration of atenolol/formoterol combination increases contractility and coronary blood flow in isolated rat hearts
HUP0201650A2 (hu) Amino-tetralin-származékok alkalmazása szív- és érrendszeri betegségek gyógykezelésére használható gyógyszerek előállítására
Kiriazis et al. Chronic activation of the low affinity site of β1‐adrenoceptors stimulates haemodynamics but exacerbates pressure‐overload cardiac remodelling
Van Zwieten α-Adrenoceptor antagonists
Gwirtz et al. RESPONSE OF CORONARY BLOOD FLOW TO ALPHA-BLOCKADE DURING SUBMTLXI~ iAL EXERCISE
EA047888B1 (ru) Применение производных пиперидин мочевины в качестве инотропных агентов
WO2024129057A1 (en) Methods of treating cardiac injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090407